MET and neoplasm: In PDX models of CRCs with moderate to high c-MET expression, a single dose of 1 mg/kg of TR1801-ADC resulted in complete tumor regression lasting for a period of 4 weeks, with no indications of tumor recurrence (Gymnopoulos et al., 2020).